Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the s2′ pocket

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7604-7617

  Hidaka, Koushi ^a   Kimura, Tooru ^a   Abdel Rahman, Hamdy M ^a   Nguyen, Jeffrey Tri ^a   McDaniel, Keith F ^b   Kohlbrenner, William E ^b   Molla, Akhteruzzaman ^b   Adachi, Motoyasu ^c   Tamada, Taro ^c   Kuroki, Ryota ^c   Katsuki, Noriko ^a   Tanaka, Yoshiaki ^a   Matsumoto, Hikaru ^a   Wang, Jun ^a   Hayashi, Yoshio ^a   Kempf, Dale J ^b   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b ABBOTT LABORATORIES   (United States)

^c JAPAN ATOMIC ENERGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLBENZOIC ACID; AG 1776; ALANINE; ALLOPHENYLNORSTATINE; ANILINE; ANTIRETROVIRUS AGENT; ISOLEUCINE; JE 2147; KNI 1030; KNI 1098; KNI 1128; KNI 1174; KNI 1241; KNI 1243; KNI 1249; KNI 1267; KNI 1271; KNI 1291; KNI 1292; KNI 1293; KNI 1303; KNI 1317; KNI 1350; KNI 1352; KNI 1357; KNI 1364; KNI 1365; KNI 1366; KNI 1367; KNI 1369; KNI 1370; KNI 1403; KNI 1405; KNI 1431; KNI 1433; KNI 1436; KNI 1454; KNI 1459; KNI 1465; KNI 1526; KNI 1614; KNI 1689; KNI 727; KNI 764; KNI 814; METHYL GROUP; N ( 2 CHLORO 6 FLUOROBENZYL) 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 2 CHLORO 6 METHYLBENZYL) 3 [( 2, 3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 2,6 DICHLOROBENZYL) 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 2,6 DIFLUOROBENZYL0 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 2,6 DIMETHYLBENZYL) 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 3 FLUORO 3 METHYLBENZYL) 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N ( 3 HYDROXY 2 METHYLBENZYL) 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N [ 1 PHENYLETHANE 1 YL] 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N [( 1,2 ) 2 HYDROXYINDAN 1 YL] 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N [INDAN 1 YL] 3 [( 2,3 ) 3 ( 3 HYDROXY 2 METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; N [INDAN 1 YL] 3 [( 2,3 ) 3 ( 3 HYDROXY METHYLBENZOYL)AMINO 2 HYDROXY 4 PHENYLBUTANOYL] 5,5 DIMETHYL 1,3 THIAZOLIDINE 4 CARBOXAMIDE; PROTEINASE INHIBITOR; SM 319777; STATINE DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPROTECTION REACTION; DRUG DESIGN; DRUG INHIBITION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MEMBRANE PERMEABILITY; MOLECULAR INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CELL LINE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYLBUTYRATES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 72249115565     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9005115     Document Type: Article

References (43)

1. Hoffmann, C.; Mulcahy, F. Overview of Antiretroviral Agents. In HIV Medicine 2006; Hoffmann, C., Rockstroh, J. K., Kamps, B. S., Eds.; Flying Publisher (FlyingPublisher.com): Paris, 2006; pp 94-129.
2. Chrusciel, R. A.; Strohbach, J. W. Curr. Top. Med. Chem. 2004, 4, 1097-1114.
3. Randolph, J. T.; DeGoey, D. Curr. Top. Med. Chem. 2004, 4, 1079-1095.
4. Johnson, V. A.; Brun-Vézinet, F; Clotet, B.; Gunthard, H. F.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Richman, D. D. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 2007, 15, 119-125.
5. (a) Mimoto, T.; Imai, J.; Tanaka, S.; Hattori, N.; Takahashi, O.; Kisanuki, S.; Nagano, Y.; Shintani, M.; Hayashi, H.; Sakikawa, K.; Akaji, K.; Kiso, Y. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. 1991, 39, 2465-2467.
6. (b) Mimoto, T.; Imai, J.; Tanaka, S.; Hattori, N.; Kisanuki, S.; Akaji, K.; Kiso, Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. 1991, 39, 3088-3090.
7. (c) Kiso, Y.; Matsumoto, H.; Mizumoto, S.; Kimura, T.; Fujiwara, Y.; Akaji, K. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999, 51, 59-68. (Pubitemid 29279343)
8. Baldwin, E. T.; Bhat, T. N.; Gulnik, S.; Liu, B.; Topol, I. A.; Kiso, Y.; Mimoto, T.; Mitsuya, H.; Erickson, J. W. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995, 3, 581-590.
9. Wang, Y.-X.; Freedberg, D. I.; Yamazaki, T.; Wingfield, P. T.; Stahl, S. J.; Kaufman, J. D.; Kiso, Y.; Torchia, D. A. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 1996, 35, 9945-9950.
10. Adachi, M.; Ohhara, T.; Kurihara, K.; Tamada, T.; Honjo, E.; Okazaki, N.; Arai, S.; Shoyama, Y.; Kimura, K.; Matsumura, H.; Sugiyama, S.; Adachi, H.; Takano, K.; Mori, Y.; Hidaka, K.; Kimura, T.; Hayashi, Y.; Kiso, Y.; Kuroki, R. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high resolution X-ray and neutron crystallography. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 4641-4646.
11. Kiso, Y. Design and synthesis of a covalently linked HIV-1 protease dimer analog and peptidomimetic inhibitors. J. Synth. Org. Chem., Jpn. 1998, 56, 896-907.
12. Mimoto, T.; Kato, R.; Takaku, H.; Nojima, S.; Terashima, K.; Misawa, S.; Fukazawa, T.; Ueno, T.; Sato, H.; Shintani, M.; Kiso, Y.; Hayashi, H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 1999, 42, 1789-1802.
13. Matsumoto, H.; Kimura, T.; Hamawaki, T.; Kumagai, A.; Goto, T.; Sano, K.; Hayashi, Y.; Kiso, Y. Design, synthesis, and biological evaluation of anti-HIV double-drugs: conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor through spontaneously cleavable linkers. Bioorg. Med. Chem. 2001, 9, 1589-1600.
14. Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M. F.; Maroun, V.; Nguyen, A.; Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.; Erickson, J.; Mitsuya, H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PIresistant HIV-1. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8675-8680.
15. (a) Mimoto, T.; Terashima, K.;Nojima, S.; Takaku, H.;Nakayama, M.; Shintani, M.; Yamaoka, T.; Hayashi, H. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg. Med. Chem. 2004, 12, 281-293.
16. (b) Mimoto, T.; Nojima, S.; Terashima, K.; Takaku, H.; Shintani, M.; Hayashi, H. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoylallophenylnorstatine structure. Bioorg. Med. Chem. 2008, 16, 1299-1308.
17. Vega, S.; Kang, L. W.; Velazquez-Campoy, A.; Kiso, Y.; Amzel, L. M.; Freire, E. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins: Struct., Funct., Bioinf. 2004, 55, 594-602. (Pubitemid 38620084)
18. Reiling, K. K.; Endres, N. F.; Dauber, D. S.; Craik, C. S.; Stroud, R. M. Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 Åstructure. Biochemistry 2002, 41, 4582-4594.
19. Hidaka, K.; Kimura, T.; Ruben, A. J.; Uemura, T.; Kamiya, M.; Kiso, A.; Okamoto, T.; Tsuchiya, Y.; Hayashi, Y.; Freire, E.; Kiso, Y. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg. Med. Chem. 2008, 16, 10049-10060.
20. Abdel-Rahman, H. M.; El-Koussi, N. A.; Alkaramany, G. S.; Youssef, A. F.; Kiso, Y. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine. Arch. Pharm. (Weinheim, Ger.) 2004, 337, 587-598.
21. Munshi, S.; Chen, Z.; Li, Y.; Olsen, D. B.; Fraley, M. E.; Hungate, R. W.; Kuo, L. C. Rapid X-ray diffraction analysis of HIV-1 protease-inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme. Acta Crystallogr., Sect.D1998, 54, 1053-1060.
22. (a) Kimura, T.; Hidaka, K.; Tanaka, Y.; Matsumoto, H.; Matsui, Y.; Abdel-Rahman, H. M.; Hayashi Y.; Kiso, Y. Identification of Dipeptide-Type HIV-1 Protease Inhibitors with High Antiviral Activity. Presented at the 5th AFMC International Medicinal Chemistry Symposium, Kyoto, Japan, Oct 2003.
23. (b) Kimura, T.; Hidaka, K.; Tanaka, Y.; Matsumoto, H.; Abdel-Rahman, H. M.; Rajesh, S.; Wang, J.; Ami, E.; Hayashi, Y.; Kiso, Y. Discovery of Potent HIV-1 Protease Inhibitors Containing Allophenylnorstatine Based on a Transition- State Mimic. Presented at the 3rd General Meeting of the International Proteolysis Society/International Conference on Protease Inhibitors, Nagoya, Japan, Nov 2003.
24. (c) Kimura, T.; Hidaka, K.; Abdel-Rahman, H.M.;Matsumoto, H.; Tanaka, Y.;Matsui, Y.; Hayashi, Y.; Kiso, Y. Design and Synthesis of Dipeptide-Type HIV-1 Protease Inhibitors with High Antiviral Activity. In Peptide Science 2003; Ueki, M., Ed.; The Japanese Peptide Society:Osaka, Japan, 2004; pp 241-244.
25. (a) Canon-Koch, S. S.; Alexander, T. N.; Barvian, M.; Bolton, G.; Boyer, F. E.; Burke, B. J.; Holler, T.; Jewell, T. M.; Prasad, J. V.; Kucera, D. J.; Linton, M. A.; Machak, J.; Mitchell, L. J.; Murphey, S. T.; Reich, S. H.; Skalitzky, D. J.; Tatlock, J. H.; Varney, M. D.; Virgil, S. C.; Webber, S. E.; Worland, S. T; Melnick, M. PatentWO 02/100844, 2002.
26. (b) Canon-Koch, S. S.; Alexander, T. N.; Barvian, M.; Bolton, G.; Boyer, F. E.; Burke, B. J.; Holler, T.; Jewell, T. M.; Prasad, J. V.; Kucera, D. J.; Machak, J.; Mitchell, L. J.; Murphey, S. T.; Reich, S. H.; Skalitzky,D. J.; Tatlock, J. H.;Varney,M. D.;Virgil, S. C.; Worland, S. T; Melnick, M.; Linton, M. A.; Webber, S. E. PCT Patent WO 02/100845, 2002.
27. (a) Hidaka, K.; Kimura, T.; Hayashi, Y.; McDaniel, K. F.; Dekhtyar, T.; Colletti, L.; Kiso, Y. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere. Bioorg. Med. Chem. Lett. 2003, 13, 93-96.
28. 2 ligands. Bioorg. Med. Chem. Lett. 2003, 13, 3657-3660.
29. Sohma, Y.; Hayashi, Y.; Ito, T.; Matsumoto, H.; Kimura, T.; Kiso, Y. Development of water-soluble prodrug of the HIV-1 proteaase inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spotaneous chemical cleavage. J. Med. Chem. 2003, 46, 4124-4135.
30. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity. A rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
31. Stanton, D. T.; Jurs, P. C. Development and use of charged partial surface area structural descriptors in computer assisted quantitative structure property relationship studies. Anal. Chem. 1990, 62, 2323-2329.
32. Wildman, S. A.; Crippen, G. M. Prediction of physiochemical parameters by atomic contributions. J. Chem. Inf. Comput. Sci. 1999, 39, 868-873.
33. Miller, J. F.; Andrews, C. W.; Brieger, M.; Furfine, E. S.; Hale, M. R.; Hanlon, M. H.; Hazen, R. J.; Kaldor, I.; McLean, E. W.; Reynolds, D.; Sammond, D. M.; Spaltenstein, A.; Tung, R.; Turner, E. M.; Xu, R. X.; Sherrill, R. G. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg. Med. Chem. Lett. 2006, 16, 1788-1794.
34. (a) Leonard, J. T.; Roy, K.QSARbyLFERmodel of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques. Bioorg. Med. Chem. 2006, 14, 1039-1046.
35. (b) Garg, R.; Patel, D. Hydrophobicity in the design of P2/P20 tetrahydropyrimidinone HIV protease inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3767-3770.
36. (c) Bhhatarai, B.; Garg, R. From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran- 2-ones HIV-1 protease inhibitors. Bioorg. Med. Chem. 2005, 13, 4078-4084.
37. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
38. (a) Martinez-Picado, J.; Savara, A. V.; Sutton, L.; D'Aquila, R. T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73, 3744-3752. (Pubitemid 29189817)
39. (b) Condra, J. H.; Schleif,W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Shivaprakash, M.; Titus, D.; Yang, T.; Teppler, H.; Squires, K. E.; Deutsch, P. J.; Emini, E. A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374, 569-571.
40. Mo, H.; Lu, L.; Dekhtyar, T.; Stewart, K. D.; Sun, E.; Kempf, D. J.; Molla, A. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Res. 2003, 59, 173-180. (Pubitemid 36966749)
41. Zhao, C.; Sham, H. L.; Sun, M.; Stoll, V. S.; Stewart, K. D.; Lin, S.; Mo, H.; Vasavanonda, S.; Saldivar, A.; Park, C.; McDonald, E. J.; Marsh, K. C.; Klein, L. L.; Kempf, D. J.; Norbeck, D. W. Synthesis and activity ofN-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains. Bioorg. Med. Chem. Lett. 2005, 15, 5499-5503.
42. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol.276, pp 307-326. (Pubitemid 27085611)
43. Sheldrick, G. M.; Schneider, T. R. SHELXL: High-Resolution Refinement. In Methods in Enzymology; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol.277, pp 319-343.